BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

By WebmasterApril 1, 2021November 1st, 2024No Comments

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

See more here

Previous PostImmunome Appoints Corleen Roche as Chief Financial Officer
Next PostImmunome Appoints Dr. Dennis Giesing as Chief Development Officer

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostImmunome Appoints Corleen Roche as Chief Financial Officer

Next PostImmunome Appoints Dr. Dennis Giesing as Chief Development Officer